Startups
Die Kurzprofile der Startups finden Sie hier:
Kurzprofile
-
Medical field: Infectious diseases
Product type: Medical devices, diagnostics and therapeutics
Growth stage: Development
Team: 30 people
Description of product:
Unyvero A30 SHR (Sepsis Host Response) is a blood-based, host response gene expression test, used to diagnose sepsis. A30 SHR can help doctors to quickly and accurately assess whether or not an infection condition in a patient has a risk of complication and developing into sepsis. Early and accurate diagnosis result of A30 SHR can also help doctors to determine the appropriate next steps for patient management.
Desired project goal:
The company would like to test-bed their new Unyvero A30 SHR test that will develop AcuSept (sepsis host-response PCR test function) into Unyvero A30 cartridge and instrument platform. To do so, the company is intending to conduct a (i) pre-clinical trial including feasibility studies, design and development and bench testing; as well as (ii) clinical trial with around 200 patients to be recruited in Germany. The company would like to collaborate with Charité to define study protocol and regulatory compliance regulations.
Desired project type:
Test bedding and validation.
-
Medical field: Rehabilitation, Robotics
Product type: Connected Care, Medical devices, diagnostics and therapeutics, Care Settings and Processes
Growth stage: Positioning for Scale
Team: >30 people
Description of product:
Articares is a leading innovator in intelligent rehabilitation technology, where they provide friendly, portable, and clinically validated tools for personalized and adaptive rehabilitation throughout the continuum of care. The compay’s suite of robotic therapy system can be set up at home by a non-technical caregiver or even by the patient alone. The robot’s smart, human-like control ensures the patient will always receive therapy suited to their current level of recovery. Through the Care Platform, clinicians are able to supervise and motivate their patients remotely while building up the patient’s trust and confidence.
Desired project goal:
The company would like to partner with Charité and BIH to be the first to deploy robotics at home in Europe. The company proposes a tele-monitored robot-aided therapy (RAT) at home model that will minimize risks by substituting supervised care in-clinic with a minimally supervised home-based model of care, leading to a reduced number of visits to the clinic while sharply increasing therapy compliance. The main outcomes of the proposal are an increase in therapist productivity, increase of quality therapy delivered to patients and overall reduction of costs for all involved stakeholders.
Desired project type:
Piloting of new care model
-
Medical field: Cancer/Oncology
Product type: Advanced technologies (AI and deep learning, VR and simulation, novel materials
Growth stage: Positioning for scale
Team: 13 people
Description of product:
Based on RNA-Seq on FFPE slides, we report epigenomic information such as gene fusion, gene expression, and alternate isoform readouts and provide clinically validated algorithmic outputs that provide likelihood of response to immunotherapy and to treatment regimes in successfully concluded clinical trials. We can provide an epigenomic report (RNA-Seq based) or an integrated genomic/epigenomic report (DNA-Seq and RNA-Seq based), with the latter comprising standard genomic readouts such as mutation and copy number variant calls.
Desired project goal:
Test bedding of EPI-Call™ (comprehensive molecular profiling test for therapy selection in late-stage cancer patients) in Charité for clinical (trial) use:
- EPI-Call™ reports epigenomic information that can be used to guide therapy selection for late stage cancer patients.
- The epigenomic information provided for by EPI-Call™ may also be used in a clinical trial setting for patient recruitment and/or biomarker discovery.
- In particular, EPI-Call™ can be deployed for use in GI cancers.
Desired project type:
Test bedding and validation.
-
Medical field: Cancer, Urology
Product type: Medical devices, diagnostics and therapeutics
Growth stage: Proof of Concept
Team: 10 people
Description of product:
The VECanDx™ ELISA kit from BioCheetah is designed to quantitatively measure patented protein biomarkers in urine specimens from high-risk individuals or persons with hematuria to aid in the diagnosis of bladder cancer.
Desired project goal:
Evaluation of the clinical performance of VECanDx™ for monitoring bladder cancer recurrence after treatment in Charité. ELISA testing of urine samples collected from Charité will be conducted, with the data compared with cystoscopy results for clinical monitoring performance studies.
BioCheetah would like to identify a clinical investigator to work with them on this project. The ideal clinical investigator should be a urologist with an interest in bladder cancer and supportive of the usage of biomarkers for the early detection and recurrence monitoring of bladder cancer.
Desired project type:
Test bedding and validation.
-
Medical field: Pulmonary and infectious diseases
Product type: Medical devices, diagnostics and therapeutics
Growth stage: Other
Team: 150 people
Description of product:
The VitaSIRO solo™ platform integrates a full workflow of nucleic acid extraction and real-time Polymerase Chain Reaction (real-time PCR) testing in a cartridge-based design. The instrument with expanded multiplex capacity can detect up to 6 targets with a wide range of sample types. The VitaSIRO solo™ SARS-CoV-2/Flu/RSV Assay performed on the automated VitaSIRO solo™ Instrument is a multiplex real-time reverse transcription polymerase chain reaction (RT-PCR) in vitro diagnostic test. It is intended for simultaneous qualitative detection and differentiation of nucleic acids from SARS-CoV-2, Flue A, Flu B and respiratory syncytial virus (RSV) in nasal swab and nasopharyngeal swab (NPS) specimens collected from individuals displaying signs and/or symptoms of respiratory tract infection.
Desired project goal:
On-site validation project to evaluate the sensitivity, specificity, positive predictive value, negative predictive value and usability of their multiplex diagnostics assay in real point-of-care scenarios. The assay targets SARS-CoV-2, Flu A, Flu B and RSV.
Desired project type:
Test bedding and validation.
-
Medical field: Other
Product type: Medical Devices, Diagnostics, and Therapeutics
Growth stage: Transition to Scale
Team: 4 people
Description of product:
uSINE is an AI ultrasound guidance software that automatically identifies spinal landmarks during pre-procedural neuraxial ultrasonography. uSINE has been shown to increase the first-needle puncture success rate of spinal anaesthesia.
Desired project goal:
Test-bedding of uSINE with the anaesthesia department to show proof of value of uSINE for eventual clinical adoption in Charité. The project can include a randomized control trial on 100 challenging patients (obese or with landmarks that are difficult-to-palpate), and comparing the first-attempt puncture success rate and time taken for 50 patients under palpation and 50 patients using uSINE with ultrasound. Proposed outcomes include obtaining usability and clinical feedback to show ease-of-use of uSINE software for widespread adoption of neuraxial ultrasonography.
Desired project type:
Test bedding and validation.
-
Medical field: Pulmonary
Product type: Connected Care; Medical Devices, Diagnostics and Therapeutics
Growth stage: Proof of Concpet
Team: 2 people
Description of product:
Meracle developed the Whizz, a simple, intuitive and convenient solution to improve the management of chronic respiratory conditions by increasing the efficiency of medication delivered into the lungs while tracking intake data to augment the management and assessment of treatment outcomes. The Whizz is the only solution in the market that addresses technique and compliance at the same time, solving the challenges faced by 7 in 10 patients, who struggle with ineffective and inconsistent inhaled medication intake.
Desired project goal:
Meracle would like to test-bed the Whizz at Charité and validate the device’s utility in the German healthcare system. The trial will encompass working with clinicians and nurses in specialist or primary care, to implement the Whizz in their current workflow, quantify clinical and health economic benefits and collect feedback from users and stakeholders.
Meracle seeks collaboration from specialist or primary care providers, such as pulmonologist, Respirologist or Allergist who treat and manage patients with moderate to severe asthma.
Desired project type:
Clinical and performance evaluation
-
Medical field: Cancer
Product type: Medical Devices, Diagnostics, and Therapeutics
Growth stage: Positioning for Scale
Team: 23 people
Description of product:
MammoReady™ is a DNA test to help patients understand their risks of developing breast cancer in the next 5 years based on three key risk analyses: monogenic, polygenic and clinical risk models. The test report also comes with actionable recommendations extracted form established guidelines.
Desired project goal:
Test-bedding of MammoReady™ as a risk stratification solution for breast cancer, with the project scope of (a) clinical validation, (b) pilot study and (c) cost-effectiveness study.
- Validation of MammoReady™’s risk prediction model with application of several testing criteria, such as risk model discrimination and risk model predictive ability.
- Pilot study (randomized clinical trial) mirroring GenoVA study in the US to assess clinical utility of MammoReady™ as a personalized risk screening tool compared to current standard of care.
- Cost-effectiveness study of integrating MamomReady™ in the patient journey from the societal, payor and health sector perspectives compared to current standard of care.
Desired project type:
Test bedding and validation.
-
Medical field: Orthopedic surgery
Product type: Medical devices, diagnostics and therapeutics
Growth stage: Positioning for scale
Team: 10 people
Description of product:
QuantumTx uses proprietary Magnetic Mitohormesis (MM) technology to effortlessly activate muscle-mitochondria, effecting natural benefits of exercise without physical strain. Their first product is the BIXEPS Fitness Device (CE Mark Fitness Equipment) which with regular weekly 10-minutes sessions, have helped thousands of seniors to improve in their functional performance.
Desired project goal:
Based on Magnetic Mitohormesis, the company has developed their next Medical Devices (currently under US FDA 510K review) indicated for improving muscle health. The company is looking for partners to validate its utility in enhancing chronic rehabilitation outcomes, as well as managing chronic age-related chronic diseases like Sarcopenia and Osteoarthritis.
The company would like to test-bed the MM medical device in the 2 following areas:
MM as a supplementary intervention for the management of mild to moderate knee OA in the community.
MM as a supplementary prehabilitation and post-surgery recovery tool for moderate to severe knee OA.
Desired project type:
Test bedding and validation.
-
Medical field: Cancer
Product type: Medical Devices, Diagnostics, and Therapeutics
Growth stage: Other
Team: <10 people
Description of product:
Restalyst has successfully developed and launched three cancer tests for early detection of cancer for nose, stomach and liver cancer.
- GC-REAAD™ ITIH3 ELISA is intended for qualitative and semi-quantitative detection of human Inter-alpha-trypsin inhibitor heavy chain H3 (ITIH3) proteins which aid in the diagnosis of gastric cancer.
- HCC-REEAD™ ERBB3 ELISA is intended for qualitative and semi-quantitative detection of human epidermal growth factor receptor 3 (ERBB3) proteins, aiding in the diagnosis of Hepatocellular Carcinoma.
Desired project goal:
The company is proposing the following project scopes:
- Clinical evaluation of GC-REAAD™ ITIH3 and HCC-REAAD™ ERBB3 ELISA using retrospective cohort of samples
- Performance evaluation under IVDR of GC-REAAD™ ITIH3 and HCC-REAAD™ ERBB3 ELISA
Desired project type:
Co-innovation, clinical and performance evaluation